Autres langues SSY Group Limited

Actions

2005

KYG8406X1034

Marché Fermé - Hong Kong S.E. Autres places de cotation 10:08:20 26/04/2024			Varia. 5j.	Varia. 1 janv.
4,79 ^HKD	+1,05 %		+1,70 %	-3,04 %

16/04	Le groupe SSY enregistre une hausse de près de 15 % de son bénéfice au premier trimestre	MT
08/04	SSY Group fournit des mises à jour sur les infections respiratoires et les médicaments contre l'hypertension	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

SSY Group Get Production, Registration Approval for Pneumonia Drug from Chinese Regulator	23/04
SSY Group Logs Nearly 15% Boost in Q1 Profit	16/04
SSY Group Provides Updates on Respiratory Infection, Hypertension Drugs	08/04
SSY Group Limited Announces Update on Product Development	08/04
SSY Group's Two Drugs Get China's NMPA's Nod for Production and Registration	03/04
SSY Group Limited Provides Update on Product Development	03/04
SSY Group's Profit Jumps 17% in 2023	27/03
SSY Group Limited Announces Final Dividend for the Year Ended 31 December 2023, Payable on 04 June 2024	27/03
SSY Group Limited Reports Earnings Results for the Full Year Ended December 31, 2023	27/03
SSY Group Obtains Drug Administration Approval for Diabetes Drug	25/03
SSY Gets Registration Approval for Parkinson’s Drug from Chinese Regulator	20/03
SSY Group Limited Announces Update on Product Development	20/03
SSY Group Gets Bulk Drug Approval from Chinese Authorities	01/03
SSY Group’s Angina Drug Gets Production, Registration Go-Ahead from Chinese Regulator	01/03
SSY Group Limited Obtains Approval for Drug Production and Registration for Nicorandil for Injection from the National Medical Products Administration of China	01/03
SSY Group Limited Announces its Norepinephrine Bitartrate Obtains the Approval for Registration from the National Medical Products Administration of China to Become a Bulk Drug for the Preparations on the Market	29/02
SSY Group’s Blood Sugar Level Drug Passes Chinese Regulator’s Quality and Efficacy Consistency Evaluation	27/02
SSY Group Limited Receives Approval for Gliclazide Tablet	27/02
China Gives Drug Production Nod to SSY's Sodium Bicarbonate Ringer's Injection	23/02
SSY Group Limited Provides Update on Product Development	23/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues SSY Group Limited

Actions

2005

KYG8406X1034

Autres langues

Filtres